IMUX Immunic Inc

$IMUX I’ve made and lost thousands in biotech over the last 7 years, the last clinical stage one I owned didn’t impress in Phase 2B and went under, lost me $55,000. this is the only bio left that I own, although not as big of a position this time. This will probably be my last go at these high risk companies as I just found out I have baby on the way! I really like the potential here, my average $10.66 and I’m still adding a bit more for the next few weeks, good luck to everyone. If successful I think it’s worth $50-$100 minimum.

$IMUX I’ll admit it. I’m nearly all in here with 30k shares and have lost almost $400K paper in just under 6 weeks Most I’ve ever dropped in a short period Need to get that off the chest Good luck to us as we need it

$IMUX I believe shorts will now start covering after dismal NVS results. We will see gradual increase in share price until ENSURE results are announced

$IMUX Toronto looked like a win. 4 posters, strong engagement around the paper posters and a busy booth. More importantly, the story keeps expanding beyond RMS into disability progression, Nurr1/neuroprotection and progressive MS. ENSURE remains the key catalyst, but the potential franchise value keeps getting more interesting.

$IMUX Michael Bonney becoming Chairman is still one of the most interesting moves IMUX made this year. Biogen/MS experience, successful commercialization, then led Cubist before its $9.5B acquisition by Merck. If ENSURE hits, I don’t want a cheap early buyout. Build the value through NDA/FDA and negotiate from strength. Bonney is exactly the type of Chairman you want in that situation.

$IMUX looks like remibrutinib results are not stellar. NVS stock lost big after the presentation

$IMUX it appears to be trading lower than cash value. Data coming, 100% buy by analysts. Added below 8. Let's moon 🚀

$IMUX if Vido beats Remi, then Vido becomes SoC. I believe all big pharma with MS franchise will bid IMUX

$IMUX Another encouraging update from $IMUX. The new CALLIPER data support sustained disability benefits, while the Nurr1 and EBV findings continue to strengthen the science behind vidofludimus calcium. The disability improvement signals are particularly interesting. Still need Phase 3 confirmation, but the overall picture continues to look promising. All eyes on ENSURE topline!

$IMUX I've seen this story play out a million times. And the next thing you're telling yourself is damn it why didn't I buy when it was down that low

$IMUX estimated data release? Didn’t they already have positive data before phase 3. Looking good to buy I think

$IMUX reminder for my fellow longs - price doesn’t matter until phase 3 results are out. $100 or $0 after that. $8 or $16 doesn’t matter!

Latest company news, October 19, 2026: Immunic appointed Jaa Roberson as Chief People Officer, a newly created role, ahead of the pivotal Phase 3 ENSURE read-out expected by the end of 2026. Immunic $IMUX Stock Hub Not investment advice. More details in our stock hub.

$IMUX Poster Title: Evaluation of Disability Outcomes from the Open-Label Extension of CALLIPER: A Phase 2 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Poster Title: Vidofludimus Calcium Requires Nurr1 to Promote Neuronal Survival In Vitro and Is Associated with Neuroprotective Effects in Murine Models of Multiple Sclerosis Poster Title: Anti-EBV T-cell Receptor Repertoire Reduction Is Linked to Enhanced Cognitive Performance in Progressive Multiple Sclerosis: Evidence from the Phase 2 CALLIPER Trial with Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor Poster Title: Bidirectional Disability Changes in Progressive Multiple Sclerosis Patients: a Proposed Endpoint to Capture Full Treatment Effects

$IMUX Absolutely stomach churning. My paper clip collection has a larger market cap now.

$IMUX wtf! The company has $160M in assets and $32M in liabilities. i.e. The shareholders value is $132M. The outstanding number of shares is 13.64M. This means $9.67 per share yet the share price is at $6.89 trading below the book value at 71% from the book value. crazy

$IMUX I’m not selling. Going to fluctuate until phase 3 results announced. If in line with phase 2, we will see a considerable pop IMO, as fda approval will be very likely. I’ve been in IOVA for a while and watched MM’s short it to hell, choose to add throughout the drop and glad I did. Hoping IMUX will be similar

$IMUX What the actual fuck...down 12% on nothing - unless there IS something we don't know about.

$IMUX for all the red days, following the readout coming here soon I hope this thing really pops

$IMUX Immunic to present new clinical, biomarker and preclinical data on Vidofludimus Calcium at MSToronto2026